Receptor binding studies disclose a novel class of high‐affinity inhibitors of the Escherichia coli FimH adhesin

Mannose‐binding type 1 pili are important virulence factors for the establishment of Escherichia coli urinary tract infections (UTIs). These infections are initiated by adhesion of uropathogenic E. coli to uroplakin receptors in the uroepithelium via the FimH adhesin located at the tips of type 1 pili. Blocking of bacterial adhesion is able to prevent infection. Here, we provide for the first time binding data of the molecular events underlying type 1 fimbrial adherence, by crystallographic analyses of the FimH receptor binding domains from a uropathogenic and a K‐12 strain, and affinity measurements with mannose, common mono‐ and disaccharides, and a series of alkyl and aryl mannosides. Our results illustrate that the lectin domain of the FimH adhesin is a stable and functional entity and that an exogenous butyl α‐ d‐mannoside, bound in  the  crystal  structures,  exhibits  a  significantly better affinity for FimH (Kd = 0.15 µM) than mannose (Kd = 2.3 µM). Exploration of the binding affinities of α‐ d‐mannosides with longer alkyl tails revealed affinities up to 5 nM. Aryl mannosides and fructose can also bind with high affinities to the FimH lectin domain, with a 100‐fold improvement and 15‐fold reduction in affinity, respectively, compared with mannose. Taken together, these relative FimH affinities correlate exceptionally well with the relative concentrations of the same glycans needed for the inhibition of adherence of type 1 piliated E. coli. We foresee that our findings will spark new ideas and initiatives for the development of UTI vaccines and anti‐adhesive drugs to prevent anticipated and recurrent UTIs.

[1]  T. Sun,et al.  In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[2]  QUANTITATIVE STUDIES , 1967 .

[3]  R Möllby,et al.  Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. , 2000, The Journal of infectious diseases.

[4]  W. Stamm,et al.  Urinary tract infection , 2010 .

[5]  G. Waksman,et al.  Structural biology of bacterial pathogenesis. , 2004, Current Opinion in Structural Biology.

[6]  R. Kolter,et al.  Genetic analysis of Escherichia coli biofilm formation: roles of flagella, motility, chemotaxis and type I pili , 1998, Molecular microbiology.

[7]  A. Levitzki,et al.  An accurate method for determination of receptor-ligand and enzyme-inhibitor dissociation constants from displacement curves. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Hultgren,et al.  Bacterial Invasion Augments Epithelial Cytokine Responses to Escherichia coli Through a Lipopolysaccharide-Dependent Mechanism1 , 2001, The Journal of Immunology.

[9]  H. Hasman,et al.  Expression and purification of the mannose recognition domain of the FimH adhesin. , 2000, FEMS microbiology letters.

[10]  P. de Man,et al.  Bacterial virulence in urinary tract infection. , 1987, Infectious disease clinics of North America.

[11]  S. Nishimura,et al.  Inhibition of Adhesion of Type 1 Fimbriated Escherichia coli to Highly Mannosylated Ligands , 2002, Chembiochem : a European journal of chemical biology.

[12]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[13]  K R Anumula,et al.  Quantitative determination of monosaccharides in glycoproteins by high-performance liquid chromatography with highly sensitive fluorescence detection. , 1994, Analytical biochemistry.

[14]  V. Stojanoff,et al.  X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. , 1999, Science.

[15]  Stefan D Knight,et al.  Structure and Biogenesis of the Capsular F1 Antigen from Yersinia pestis Preserved Folding Energy Drives Fiber Formation , 2003, Cell.

[16]  C. Brinton Non-Flagellar Appendages of Bacteria , 1959, Nature.

[17]  G. Waksman,et al.  Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection , 2002, Molecular microbiology.

[18]  S. Oscarson,et al.  Syntheses of deoxy analogues of methyl 3,6-di-O-alpha-D-mannopyranosyl-alpha-D-mannopyranoside for studies of the binding site of concanavalin A. , 1995, Carbohydrate Research.

[19]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[20]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[21]  M. Sanner,et al.  Reduced surface: an efficient way to compute molecular surfaces. , 1996, Biopolymers.

[22]  S. Knight,et al.  Structural basis for bacterial adhesion in the urinary tract. , 2003, Advances in experimental medicine and biology.

[23]  T. Silhavy,et al.  On the significance of the retention of ligand by protein. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Glockshuber,et al.  Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. , 2001, Journal of cell science.

[25]  G. Waksman,et al.  Structural Basis of the Interaction of the Pyelonephritic E. coli Adhesin to Its Human Kidney Receptor , 2001, Cell.

[26]  A. Vagin,et al.  MOLREP: an Automated Program for Molecular Replacement , 1997 .

[27]  S. Langermann,et al.  Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. , 1997, Science.

[28]  S. Falkow,et al.  Frequency among Enterobacteriaceae of the DNA sequences encoding type 1 pili , 1985, Journal of bacteriology.

[29]  N. W. Davis,et al.  The complete genome sequence of Escherichia coli K-12. , 1997, Science.

[30]  Lode Wyns,et al.  The fimbrial adhesin F17‐G of enterotoxigenic Escherichia coli has an immunoglobulin‐like lectin domain that binds N‐acetylglucosamine , 2003, Molecular microbiology.

[31]  J. Berglund,et al.  Bacterial adhesins: structural studies reveal chaperone function and pilus biogenesis. , 2000, Current opinion in chemical biology.

[32]  Dina,et al.  Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated Escherichia coli to eucaryotic cells , 1989, Antimicrobial Agents and Chemotherapy.

[33]  N. Firon,et al.  Carbohydrate-binding sites of the mannose-specific fimbrial lectins of enterobacteria , 1984, Infection and immunity.

[34]  N. Brown,et al.  Molecular Microbiology , 1998, NATO ASI Series.

[35]  M. Mulvey,et al.  Adhesion and entry of uropathogenic Escherichia coli , 2002, Cellular microbiology.

[36]  M. Footer,et al.  Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Hultgren,et al.  PapD-like chaperones and pilus biogenesis. , 2000, Seminars in cell & developmental biology.

[38]  C. Bloch,et al.  A key role for type 1 pili in enterobacterial communicability , 1992, Molecular microbiology.

[39]  Thisbe K Lindhorst,et al.  Inhibition of the type 1 fimbriae-mediated adhesion of Escherichia coli to erythrocytes by multiantennary α-mannosyl clusters: The effect of multivalency , 1998, Glycoconjugate Journal.

[40]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[41]  S. Hultgren,et al.  The chaperone/usher pathway: a major terminal branch of the general secretory pathway. , 1998, Current opinion in microbiology.

[42]  J. Walker,et al.  Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. , 1996, Journal of molecular biology.

[43]  D. Stevens,et al.  Structural Biology of Bacterial Pathogenesis , 2006, Emerging Infectious Diseases.

[44]  C. Tang,et al.  Type 1 fimbriae and extracellular polysaccharides are preeminent uropathogenic Escherichia coli virulence determinants in the murine urinary tract , 2002, Molecular microbiology.

[45]  S. Oscarson,et al.  Syntheses of the octyl and tetradecyl glycosides of 3,6-di-O-α-d-mannopyranosyl-α-d-mannopyranose and of 3,4-di-O-α-d-mannopyranosyl-α-d-mannopyranose. A new way for 2,4-di-O-protection of mannopyranosides , 1993 .

[46]  L. Wyns,et al.  Structural basis of carbohydrate recognition by the lectin LecB from Pseudomonas aeruginosa. , 2003, Journal of molecular biology.

[47]  J Navaza,et al.  Implementation of molecular replacement in AMoRe. , 2001, Acta crystallographica. Section D, Biological crystallography.

[48]  Ankur H. Shah,et al.  Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection. , 1997, The Journal of clinical investigation.

[49]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[50]  R. Bollinger,et al.  Immunoglobulin-Mediated Agglutination of and Biofilm Formation by Escherichia coli K-12 Require the Type 1 Pilus Fiber , 2004, Infection and Immunity.

[51]  M. Schembri,et al.  Global gene expression in Escherichia coli biofilms , 2003, Molecular microbiology.

[52]  W. Wooster,et al.  Crystal structure of , 2005 .

[53]  A. Lundblad,et al.  The Pk Antigen as Receptor for the Haemagglutinin of Pyelonephritic Escherichia coli , 1980 .

[54]  A. Schaeffer,et al.  Role of type 1 pili and effects of phase variation on lower urinary tract infections produced by Escherichia coli , 1985, Infection and immunity.

[55]  N. Firon,et al.  Carbohydrate specificity of the surface lectins of Escherichia coli, Klebsiella pneumoniae, and Salmonella typhimurium. , 1983, Carbohydrate research.

[56]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[57]  Jörgen Ohlsson,et al.  Quantitative studies of the binding of the class II PapG adhesin from uropathogenic Escherichia coli to oligosaccharides. , 2003, Bioorganic & medicinal chemistry.

[58]  L. Wyns,et al.  Crystal Structure of Pterocarpus angolensis Lectin in Complex with Glucose, Sucrose, and Turanose* , 2003, The Journal of Biological Chemistry.

[59]  R. Glockshuber,et al.  Localization of uroplakin Ia, the urothelial receptor for bacterial adhesin FimH, on the six inner domains of the 16 nm urothelial plaque particle. , 2002, Journal of molecular biology.

[60]  S. Normark,et al.  The PapG protein is the alpha-D-galactopyranosyl-(1----4)-beta-D-galactopyranose-binding adhesin of uropathogenic Escherichia coli. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[61]  S. Langermann,et al.  Development of a recombinant FimCH vaccine for urinary tract infections. , 2003, Advances in experimental medicine and biology.

[62]  Quincy Teng,et al.  Structural Biology , 2013, Springer US.

[63]  S. Falkow,et al.  Construction and expression of recombinant plasmids encoding type 1 or D-mannose-resistant pili from a urinary tract infection Escherichia coli isolate , 1981, Infection and immunity.

[64]  Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. , 1998 .

[65]  D. Old Inhibition of the interaction between fimbrial haemagglutinins and erythrocytes by D-mannose and other carbohydrates. , 1972, Journal of general microbiology.

[66]  H. Leffler,et al.  Chemical identification of a glycosphingolipid receptor for Escherichia coli attaching to human urinary tract epithelial cells and agglutinating human erythrocytes , 1980 .

[67]  N. Firon,et al.  Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells , 1987, Infection and immunity.

[68]  N. Firon,et al.  Interaction of mannose-containing oligosaccharides with the fimbrial lectin of Escherichia coli. , 1982, Biochemical and biophysical research communications.

[69]  A. Schaeffer,et al.  Urinary tract infection in adults: research priorities and strategies. , 2001, International journal of antimicrobial agents.

[70]  H. Mizoguchi,et al.  Extensive Genomic Diversity in Pathogenic Escherichia coli and Shigella Strains Revealed by Comparative Genomic Hybridization Microarray , 2004, Journal of bacteriology.

[71]  H R Powell,et al.  The Rossmann Fourier autoindexing algorithm in MOSFLM. , 1999, Acta crystallographica. Section D, Biological crystallography.

[72]  G. Waksman,et al.  Structural basis of chaperone function and pilus biogenesis. , 1999, Science.

[73]  R M Esnouf,et al.  An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. , 1997, Journal of molecular graphics & modelling.

[74]  B. Koellreutter,et al.  Oligomannoside-type glycopeptides inhibiting adhesion of Escherichia coli strains mediated by type 1 pili: preparation of potent inhibitors from plant glycoproteins , 1986, Infection and immunity.

[75]  B. Uhlin,et al.  Regulatory cross‐talk between adhesin operons in Escherichia coli: inhibition of type 1 fimbriae expression by the PapB protein , 2000, The EMBO journal.

[76]  P Bork,et al.  The immunoglobulin fold. Structural classification, sequence patterns and common core. , 1994, Journal of molecular biology.

[77]  T. Hooton,et al.  Diagnosis and treatment of uncomplicated urinary tract infection. , 1997, Infectious disease clinics of North America.

[78]  G. Waksman,et al.  Chaperone Priming of Pilus Subunits Facilitates a Topological Transition that Drives Fiber Formation , 2002, Cell.

[79]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.